SR18662

Catalog No.S8900 Batch:S890001

Technical Data

Formula

C₁₆H₁₉Cl₂N₃O₄S

Molecular Weight

420.31

CAS No.

2505001-62-5

Solubility (25°C)*

In vitro

DMSO

84 mg/mL (199.85 mM)

Water

Insoluble

Ethanol

Insoluble

In vivo (Add solvents to the product individually and in order)

Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	1.4mg/ml	Taking the 1 mL working solution as an example, add 50 μL of clarified DMSO stock solution of 28 mg/ml to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil	0.35mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 7 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

SR18662 is an optimized compund based on ML264 that inhibits Krüppel-like factor 5 (KLF5) with IC50 of 4.4 nM. SR18662 reduces the viability of multiple colorectal cancer cell lines. SR18662 induces apoptosis.

Targets

KLF5 ^[1]
(Cell-free assay)

4.4 nM

In vitro

Treatment with SR18662 significantly reduces growth and proliferation of CRC cells. SR18662 shows improved efficacy in reducing viability of multiple CRC cell lines. Flow cytometry analysis following SR18662 treatment shows an increase in cells captured in either S or G2/M phases of the cell cycle and a significant increase in the number of apoptotic cells. SR18662 treatment also reduces the expression of cyclins and components of MAPK and WNT signaling pathways.^[1]

In vivo

A significant dose-dependent inhibition of xenograft growth in mice is observed following SR18662 treatment that exceeds the effect of ML264 at equivalent doses. SR18662 is potential for colorectal cancer therapy.^[1]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines DLD-1, HCT116, HT29 and SW620 colorectal cancer cell lines Concentrations 0.001 μM-20 μM Incubation Time 24 h Method KLF5 promoter activity assay: DLD-1/pGL4.18hKLF5p cells are seeded in 96 well plate format and treated with DMSO or with SR18662 dissolved in DMSO in the range of 0.001 to 20 μM final concentration for 24 h and the human KLF5 promoter activity is determined with the ONE-Glo luciferase assay system using a SpectramMax M3 plate reader.
Animal Study:^{^[1]}	Animal Models 7-week-old male NuJ/Foxn1^nu mice with DLD-1 human colorectal cells injected Dosages 5 mg/kg, 10 mg/kg, 25 mg/kg Administration IP

Cell Assay:^{^[1]}

Cell lines
DLD-1, HCT116, HT29 and SW620 colorectal cancer cell lines
Concentrations
0.001 μM-20 μM
Incubation Time
24 h
Method
KLF5 promoter activity assay: DLD-1/pGL4.18hKLF5p cells are seeded in 96 well plate format and treated with DMSO or with SR18662 dissolved in DMSO in the range of 0.001 to 20 μM final concentration for 24 h and the human KLF5 promoter activity is determined with the ONE-Glo luciferase assay system using a SpectramMax M3 plate reader.

Animal Study:^{^[1]}

Animal Models
7-week-old male NuJ/Foxn1^nu mice with DLD-1 human colorectal cells injected
Dosages
5 mg/kg, 10 mg/kg, 25 mg/kg
Administration
IP

References

[1] Julie Kim, et al. Mol Cancer Ther. 2019 Nov;18(11):1973-1984.

Selleck's SR18662 has been cited by 1 publication

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth [ J Exp Clin Cancer Res, 2023, 42(1):25]	PubMed: 36670508

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth [ J Exp Clin Cancer Res, 2023, 42(1):25]

PubMed: 36670508

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.